Short-term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients

References

• Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329–37
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 2001; 19: 53–61
   PubMed Web of Science ®Google Scholar
• Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648–58
   PubMed Web of Science ®Google Scholar
• Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469–76
   PubMed Web of Science ®Google Scholar
• Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998; 18: 387–94
   PubMed Web of Science ®Google Scholar
• Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998; 54: 236–44
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: 1684–8
   PubMed Web of Science ®Google Scholar
• Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61: 297–304
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22
   PubMed Web of Science ®Google Scholar
• Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004; 109(Suppl 1)1142–8
   Google Scholar
• Di Garbo V, Bono M, Di Raimondo D, De Simone R, Raneli G, Avellone G. Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response. Eur J Clin Pharmacol 2000; 56: 277–84
   PubMed Web of Science ®Google Scholar
• Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med 2000; 32: 164–76
   PubMed Web of Science ®Google Scholar
• Gotto AM, Jr, Farmer JA. Pleiotropic effects of statins: do they matter?. Curr Opin Lipidol 2001; 12: 391–4
   PubMed Web of Science ®Google Scholar
• Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary artery disease—beyond lowering cholesterol. Ann Pharmacother 2000; 34: 1432–9
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–5
   PubMed Web of Science ®Google Scholar
• Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933–5
   PubMed Web of Science ®Google Scholar
• Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002; 39: 1213–7
   PubMed Web of Science ®Google Scholar
• Panichi V, Paoletti S, Mantuano E, Manca-Rizza G, Filippi C, Santi S, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 2006; 21: 337–44
   PubMed Web of Science ®Google Scholar
• The Post Coronary Artery Bypass Graft Trial Investigators The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153–62
   PubMed Web of Science ®Google Scholar
• Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W, et al. ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21: 1779–86
   PubMedGoogle Scholar
• Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002; 17: 1513–7
   PubMed Web of Science ®Google Scholar
• Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, et al. Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients?. J Am Soc Nephrol 2001; 12: 814–21
   PubMed Web of Science ®Google Scholar
• Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999; 14: 1956–60
   PubMed Web of Science ®Google Scholar
• Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890–6
   PubMed Web of Science ®Google Scholar
• Zuckerman SH, O'Neal L. Endotoxin and GM-CSF-mediated down-regulation of macrophage apo E secretion is inhibited by a TNF-specific monoclonal antibody. J Leukoc Biol 1994; 55: 743–8
   PubMed Web of Science ®Google Scholar
• Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000; 102: 2636–42
   PubMed Web of Science ®Google Scholar
• Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042–7
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreno V, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998; 54: 1337–43
   PubMed Web of Science ®Google Scholar
• Sirken G, Kung SC, Raja R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J 2003; 49: 422–5
   PubMed Web of Science ®Google Scholar
• Jovinge S, Ares MPS, Kallin B, Nilsson J. Human monocytes/macrophages release TNF-α in response to ox-LDL. Arterioscler Thromb Vasc 1996; 16: 1573–9
   PubMed Web of Science ®Google Scholar
• Mason JC. The statins—therapeutic diversity in renal disease?. Curr Opin Nephrol Hypertens 2005; 14: 17–24
   PubMed Web of Science ®Google Scholar